Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

Cell

Volumn 162, Issue 6, 2015, Pages 1242-1256

  Kleffel, Sonja ^a   Posch, Christian ^a,b   Barthel, Steven R ^a   Mueller, Hansgeorg ^a,c   Schlapbach, Christoph ^d   Guenova, Emmanuella ^e   Elco, Christopher P ^a   Lee, Nayoung ^a   Juneja, Vikram R ^a   Zhan, Qian ^a   Lian, Christine G ^a   Thomi, Rahel ^d   Hoetzenecker, Wolfram ^e   Cozzio, Antonio ^e   Dummer, Reinhard ^e   Mihm, Martin C ^a   Flaherty, Keith T ^a   Frank, Markus H ^a,f   Murphy, George F ^a   Sharpe, Arlene H ^a   Kupper, Thomas S ^a   Schatton, Tobias ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF BERN   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f EDITH COWAN UNIVERSITY   (Australia)

Author keywords

antibody; blockade; immune checkpoint; Melanoma; mTOR signaling; p S6; PD 1; PD L1; programmed cell death 1; S6 ribosomal protein; therapy

Indexed keywords

INTERLEUKIN 2 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; PDCD1 PROTEIN, HUMAN; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IN VITRO STUDY; MELANOMA; MELANOMA B16; MELANOMA CELL LINE; MOUSE; MUTAGENESIS; NONHUMAN; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; GENE SILENCING; GENETICS; METABOLISM; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 84941367700     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.08.052     Document Type: Article

References (30)

1. N. Aceto, N. Sausgruber, H. Brinkhaus, D. Gaidatzis, G. Martiny-Baron, G. Mazzarol, S. Confalonieri, M. Quarto, G. Hu, P.J. Balwierz, and et al. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop Nat. Med. 18 2012 529 537
2. G. Civenni, A. Walter, N. Kobert, D. Mihic-Probst, M. Zipser, B. Belloni, B. Seifert, H. Moch, R. Dummer, M. van den Broek, and L. Sommer Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth Cancer Res. 71 2011 3098 3109
3. R.B. Corcoran, S.M. Rothenberg, A.N. Hata, A.C. Faber, A. Piris, R.M. Nazarian, R.D. Brown, J.T. Godfrey, D. Winokur, J. Walsh, and et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma Sci. Transl. Med. 5 2013 196ra98
4. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 2002 793 800
5. K.T. Flaherty, F.S. Hodi, and D.E. Fisher From genes to drugs: targeted strategies for melanoma Nat. Rev. Cancer 12 2012 349 361
6. J. Fourcade, Z. Sun, M. Benallaoua, P. Guillaume, I.F. Luescher, C. Sander, J.M. Kirkwood, V. Kuchroo, and H.M. Zarour Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients J. Exp. Med. 207 2010 2175 2186
7. L.M. Francisco, V.H. Salinas, K.E. Brown, V.K. Vanguri, G.J. Freeman, V.K. Kuchroo, and A.H. Sharpe PD-L1 regulates the development, maintenance, and function of induced regulatory T cells J. Exp. Med. 206 2009 3015 3029
8. M.M. Gubin, X. Zhang, H. Schuster, E. Caron, J.P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C.D. Arthur, W.J. Krebber, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
9. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
10. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, and et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 2014 563 567
11. X. Jiang, J. Zhou, A. Giobbie-Hurder, J. Wargo, and F.S. Hodi The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition Clin. Cancer Res. 19 2013 598 609
12. K.W. Liu, H. Feng, R. Bachoo, A. Kazlauskas, E.M. Smith, K. Symes, R.L. Hamilton, M. Nagane, R. Nishikawa, B. Hu, and S.Y. Cheng SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans J. Clin. Invest. 121 2011 905 917
13. A. Ostman, C. Hellberg, and F.D. Böhmer Protein-tyrosine phosphatases and cancer Nat. Rev. Cancer 6 2006 307 320
14. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat. Rev. Cancer 12 2012 252 264
15. W. Peng, C. Liu, C. Xu, Y. Lou, J. Chen, Y. Yang, H. Yagita, W.W. Overwijk, G. Lizée, L. Radvanyi, and P. Hwu PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines Cancer Res. 72 2012 5209 5218
16. C. Posch, H. Moslehi, L. Feeney, G.A. Green, A. Ebaee, V. Feichtenschlager, K. Chong, L. Peng, M.T. Dimon, T. Phillips, and et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo Proc. Natl. Acad. Sci. USA 110 2013 4015 4020
17. M.A. Postow, M.K. Callahan, and J.D. Wolchok Immune Checkpoint Blockade in Cancer Therapy J. Clin. Oncol. 33 2015 1974 1982
18. J.L. Riley PD-1 signaling in primary T cells Immunol. Rev. 229 2009 114 125
19. N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, and et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128
20. K. Sakuishi, L. Apetoh, J.M. Sullivan, B.R. Blazar, V.K. Kuchroo, and A.C. Anderson Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J. Exp. Med. 207 2010 2187 2194
21. T. Schatton, G.F. Murphy, N.Y. Frank, K. Yamaura, A.M. Waaga-Gasser, M. Gasser, Q. Zhan, S. Jordan, L.M. Duncan, C. Weishaupt, and et al. Identification of cells initiating human melanomas Nature 451 2008 345 349
22. T. Schatton, U. Schütte, N.Y. Frank, Q. Zhan, A. Hoerning, S.C. Robles, J. Zhou, F.S. Hodi, G.C. Spagnoli, G.F. Murphy, and M.H. Frank Modulation of T-cell activation by malignant melanoma initiating cells Cancer Res. 70 2010 697 708
23. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, L.A. Walsh, M.A. Postow, P. Wong, T.S. Ho, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N. Engl. J. Med. 371 2014 2189 2199
24. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr. Opin. Immunol. 24 2012 207 212
25. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, D.F. McDermott, J.D. Powderly, R.D. Carvajal, J.A. Sosman, M.B. Atkins, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2012 2443 2454
26. P.C. Tumeh, C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, and et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature 515 2014 568 571
27. J.S. Weber, S.P. D'Angelo, D. Minor, F.S. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N.I. Khushalani, W.H. Miller Jr., C.D. Lao, and et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment: a randomised, controlled, open-label, phase 3 trial Lancet Oncol. 16 2015 375 384
28. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, N.H. Segal, C.E. Ariyan, R.A. Gordon, K. Reed, and et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
29. S.R. Woo, M.E. Turnis, M.V. Goldberg, J. Bankoti, M. Selby, C.J. Nirschl, M.L. Bettini, D.M. Gravano, P. Vogel, C.L. Liu, and et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res. 72 2012 917 927
30. M. Yadav, S. Jhunjhunwala, Q.T. Phung, P. Lupardus, J. Tanguay, S. Bumbaca, C. Franci, T.K. Cheung, J. Fritsche, T. Weinschenk, and et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing Nature 515 2014 572 576